Amgen Reports First Quarter 2002 Earnings Per Share Increased 14 Percent to 32 Cents Read more about Amgen Reports First Quarter 2002 Earnings Per Share Increased 14 Percent to 32 Cents
Important Drug Warning Counterfeiting of Epogen(R) Read more about Important Drug Warning Counterfeiting of Epogen(R)
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (California) Read more about 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (California)
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Jefferson County, Kentucky) Read more about 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Jefferson County, Kentucky)
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Boulder County, Colorado) Read more about 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Boulder County, Colorado)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R) Read more about Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference Read more about Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference
Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting Read more about Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting
Amgen Statement on Successful Outcome of Romiplostim Panel Meeting Read more about Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
Amgen to Discuss Romiplostim Application at FDA ODAC Meeting Read more about Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
